Deformation-induced ATP release from red blood cells requires CFTR activity

RANDY S. SPRAGUE, MARY L. ELLSWORTH, ALAN H. STEPHENSON, MARY E. KLEINHENZ, AND ANDREW J. LONIGRO

Departments of Medicine and Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, Missouri 63104

Sprague, Randy S., Mary L. Ellsworth, Alan H. Stephenson, Mary E. Kleinhenz, and Andrew J. Lonigro.

Deformation-induced ATP release from red blood cells requires CFTR activity. Am. J. Physiol. 275 (Heart Circ. Physiol. 44): H1726–H1732, 1998.—Recently, it was reported that rabbit and human red blood cells (RBCs) release ATP in response to mechanical deformation. Here we investigate the hypothesis that the activity of the cystic fibrosis transmembrane conductance regulator (CFTR), a member of the ATP binding cassette, is required for deformation-induced ATP release from RBCs. Incubation of rabbit RBCs with either of two inhibitors of CFTR activity, glibenclamide (10 µM) or niflumic acid (20 µM), resulted in inhibition of deformation-induced ATP release. To demonstrate the contribution of CFTR to deformation-induced ATP release from human RBCs, cells from healthy humans, patients with cystic fibrosis (CF), or patients with chronic obstructive lung disease (COPD) unrelated to CF were studied. RBCs of healthy humans and COPD patients released ATP in response to mechanical deformation. In contrast, deformation of RBCs from patients with CF did not result in ATP release. We conclude that deformation-induced ATP release from rabbit and human RBCs requires CFTR activity, suggesting a previously unrecognized role for CFTR in the regulation of vascular resistance.

cystic fibrosis; chronic obstructive lung disease; nitric oxide; pulmonary circulation; vascular resistance; adenosine 5'-triphosphate; cystic fibrosis transmembrane conductance regulator

ENDOTHELIUM-DERIVED nitric oxide (NO) is considered to be an important participant in the regulation of the circulation via its ability to produce relaxation of vascular smooth muscle (11, 15). However, those mechanisms that stimulate the synthesis and release of NO under physiological conditions, for example, in response to changes in vascular resistance, are incompletely understood. A number of endogenous substances, when applied to endothelial cells in culture or to isolated blood vessels, stimulate the synthesis and release of NO (3, 5, 9). One of those substances, ATP, is contained in large amounts in red blood cells (RBCs; see Refs. 17, 24). Recently, it was reported that ATP is released in response to mechanical deformation of RBCs from humans and rabbits (24). Thus, in the intact circulation, ATP released from RBCs in response to this physiological stimulus could serve as an important determinant of NO synthesis and, thereby, vascular resistance. However, ATP is a highly charged molecule and, as such, does not readily cross cell membranes. It has been suggested that ATP may exit cells via the activity of one or more ion channels in a family referred to as the “ATP binding cassette” (27). One member of this family, the cystic fibrosis transmembrane conductance regulator (CFTR), was suggested to participate in the movement of ATP out of cells (1); however, the mechanism by which CFTR influences ATP release remains controversial. Several studies report that CFTR is, itself, an ion channel mediating ATP efflux (18, 21), whereas others suggest that ATP does not exit cells via this channel (13, 16, 20). In an attempt to reconcile these divergent points of view, it was proposed that CFTR is not the channel mediating ATP efflux but rather is a regulator of another ion channel(s) that permits the movement of ATP out of cells (14), i.e., CFTR is, as the name implies, truly a transmembrane conductance regulator for ATP (1, 14).

In the present work, we investigated the hypothesis that the release of ATP from RBCs of rabbits and humans, in response to mechanical deformation, requires the activity of CFTR. We used pharmacological inhibitors of CFTR activity as well as RBCs from patients with cystic fibrosis, who are genetically deficient in CFTR activity, to determine if CFTR is necessary for deformation-induced ATP release from RBCs.

METHODS

Preparation of RBCs. For obtaining rabbit RBCs, male New Zealand White rabbits (2.0–2.5 kg) were anesthetized with droperidol (0.1 ml/kg im) followed by pentobarbital sodium (15 mg/kg iv). After tracheostomy, the rabbits were mechanically ventilated (tidal volume 10 ml/kg, rate 20–25 breaths/min; Harvard ventilator). A catheter was placed into a carotid artery, heparin (2,000 units iv) was administered, and, after 10 min, animals were exsanguinated. For human RBCs, 60 ml of blood were collected into a syringe containing heparin (50 units) via venipuncture without the use of a tourniquet. Immediately after collection of blood from rabbits or humans, RBCs were separated from other formed elements and plasma by centrifugation at 1,000 g at 4°C for 10 min. The supernatant and buffy coat were removed by aspiration. Packed RBCs were resuspended and washed three times in a physiological salt solution (PSS: in mM: 4.7 KCl, 2.0 CaCl2, 1.2 MgSO4, 140.5 NaCl, and 21.0 tris(hydroxymethyl)aminomethane and 11.1 dextrose with 5% bovine serum albumin, pH adjusted to 7.4). RBCs were prepared on the day of use. The protocols for removal of blood from rabbits and humans were approved by the appropriate institutional review committees of Saint Louis University.

Deformation of RBCs. RBCs were subjected to mechanical deformation using the St. George’s Blood Filtrometer (Carri-
ATP content of RBCs was determined by measurement of ATP acid, the effect of these agents on the measurement of ATP that the results of the assay were not altered by the agents the luciferin-luciferase assay. All data from experiments in association with this level of hemolysis was not detectable in added to the filtrometer. The amount of ATP released in sufficiently sensitive to detect hemolysis of 0.1% of RBCs hemoglobin in the supernatant was determined by light centrifuged at 1,000 RBCs, after ATP determinations, the filter effluent was ATP measured represented that released from the lysis of hemoglobin extract (5 mg/5 ml distilled water, FLE 50; Sigma, crude firefly tail extract. A 250-µl sample of the RBC suspen-

Measurement of ATP and hemoglobin. ATP was measured by the luciferin-luciferase technique (2, 26) in which the amount of light generated by the reaction of ATP with firefly tail extract is dependent on the ATP concentration. Sensitivity was augmented by addition of synthetic D-luciferin to the crude firefly extract. A 250-µl sample of the RBC suspension fluid was injected into a cuvette containing 250 µl crude firefly tail extract (5 mg/5 ml distilled water, FLE 50; Sigma, St. Louis, MO) and 250 µl of a solution of synthetic D-luciferin (50 mg/100 ml distilled water, Sigma). The cuvette was mounted opposite a photomultiplier tube (RCA 931A) in a light-excluding box. A standard curve to ATP was obtained on the day of each experiment. To exclude the possibility that the ATP measured represented that released from the lysis of RBCs, after ATP determinations, the filter effluent was centrifuged at 1,000 g at 4°C for 10 min, and the presence of hemoglobin in the supernatant was determined by light absorption at wavelengths of 385, 405, 560, 577, and 630 nm (4, 28). This technique for hemoglobin determination is sufficiently sensitive to detect hemolysis of 0.1% of RBCs added to the filtrometer. The amount of ATP released in association with this level of hemolysis was not detectable in the luciferin-luciferase assay. All data from experiments in which free hemoglobin was detected were excluded. To ensure that the results of the assay were not altered by the agents with which RBCs were incubated, glibenclamide or niflumic acid, the effect of these agents on the measurement of ATP was determined. Neither glibenclamide nor niflumic acid, at the concentrations used in this study, altered the sensitivity of the assay for authentic ATP. Finally, in all experiments, ATP content of RBCs was determined by measurement of ATP in solution after lysis of a known number of RBCs in distilled water.

Preparation of reagents. Glibenclamide was prepared as a 0.01 M stock solution by adding 49 mg of glibenclamide to a solution containing 2 ml of 0.1 N NaOH and 7.94 ml of dextrose in distilled water (50 mg/ml) and heating it slowly to 52°C. Niflumic acid was dissolved in distilled water. All compounds were purchased from Sigma.

Deformation of rabbit RBCs in the absence and presence of inhibitors of CFTR activity. Before the passage of rabbit RBCs through the filtrometer, the cells were incubated for 30 min with one of two purported inhibitors of CFTR activity, namely, glibenclamide (10 µM, n = 5; see Refs. 22, 23) and niflumic acid (20 µM, n = 5; see Ref. 7), or with PSS. The RBCs were passed through filters with average pore diameters of 12, 8, or 5 µm. The sequence of filters was randomly assigned.

To determine whether the effect of glibenclamide on deformation-induced ATP release from RBCs was irreversible, rabbit RBCs were incubated with glibenclamide (10 µM, n = 4) for 30 min and then washed three times in PSS. Four groups of RBCs were subjected to deformation by passage through filters with an average pore diameter of 5 µm in the filtrometer. The groups were as follows: 1) control RBCs not exposed to glibenclamide, 2) RBCs exposed to glibenclamide for 30 min but not washed, 3) RBCs exposed to glibenclamide for 30 min and then washed three times, and 4) three experiments in which fresh rabbit RBCs were incubated with the supernatant obtained after the final washing of RBCs exposed to glibenclamide.

Deformation of human RBCs. Human RBCs were obtained from healthy volunteers (n = 5), patients with cystic fibrosis (n = 5), and patients with chronic obstructive pulmonary disease (n = 4) and were deformed in the filtrometer. Patients with cystic fibrosis were being treated with medications, including inhaled β-agonists (5), inhaled ipratropium bromide (4), oral pancreatic enzyme replacement (4), inhaled corticosteroids (3), oral antibiotics (3), and oral theophylline (1). All patients with chronic lung disease were being treated with inhaled β-agonists, and two were using inhaled ipratropium bromide. Healthy subjects were on no medications.

Statistical methods. Statistical significance between experi-

RESULTS

Effect of glibenclamide on deformation-induced ATP release from rabbit RBCs. Mechanical deformation of rabbit RBCs by passage through filters with average pore sizes of 12, 8, or 5 µm resulted in increments in RCTT (Fig. 1). Incubation of rabbit RBCs with glibenclamide (10 µM, n = 5) resulted in inhibition of deformation-induced ATP release. In the presence of glibenclamide, ATP concentration in the effluent of
filters with pores of 12, 8, and 5 µm decreased from control values by 37 ± 6, 55 ± 6, and 63 ± 6%, respectively (Fig. 1B). Incubation of rabbit RBCs with glibenclamide did not result in a change in RCTT compared with control RBCs (Fig. 1A). In addition, concentrations of ATP present within rabbit RBCs after incubation with glibenclamide were not different from those of untreated RBCs (Table 1).

Effect of washing on deformation-induced ATP release from rabbit RBCs incubated with glibenclamide. Neither exposure of RBCs to glibenclamide nor repeated washing resulted in any change in RCTT from control values in response to passage of cells through filters with 5-µm pores (Fig. 2A). In contrast, glibenclamide treatment resulted in inhibition of ATP release when RBCs were subjected to mechanical deformation (Fig. 2B). The inhibition of ATP release in response to mechanical deformation was not diminished after repeated washing of the RBCs (Fig. 2C). Finally, the supernatant obtained after the final wash of RBCs treated with glibenclamide, when incubated with fresh RBCs, did not alter RCTT or inhibit ATP release (Fig. 2, A and B).

Effect of niflumic acid on deformation-induced ATP release from rabbit RBCs. In the presence of niflumic acid (20 µM, n = 5), the RCTT of RBCs was unaltered (Fig. 3A). In contrast, ATP release was reduced significantly in response to passage of RBCs through filters with average pore sizes of both 8 and 5 µm after incubation with niflumic acid (Fig. 3B). The inhibition of ATP release with niflumic acid was not unlike that seen after incubation of rabbit RBCs with glibenclamide (Fig. 1B), i.e., in the presence of niflumic acid, release of ATP was reduced by 37 ± 20, 54 ± 5, and 61 ±

**Table 1. Concentration of ATP in rabbit RBCs in the absence and presence of glibenclamide and niflumic acid**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Total ATP, mM/RBC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1.9 ± 0.5</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>2.3 ± 0.7</td>
</tr>
<tr>
<td>Control</td>
<td>2.4 ± 0.8</td>
</tr>
<tr>
<td>Niflumic acid</td>
<td>2.3 ± 0.8</td>
</tr>
</tbody>
</table>

Values are means ± SE, n = 5 experiments/group. RBCs, red blood cells.
6% in response to passage through filters with pore sizes of 12, 8, and 5 µm, respectively. Niflumic acid was without effect on the concentration of ATP in the RBCs (Table 1).

Effect of mechanical deformation on ATP release from RBCs of healthy humans and humans with cystic fibrosis. The finding that the genetic defects of cystic fibrosis result in abnormal expression or processing of CFTR (8) provides a unique opportunity to examine the contribution of this channel to mechanical deformation-induced ATP release from human RBCs. RBCs obtained from healthy humans (n = 5) released ATP in response to mechanical deformation in a stimulus-dependent fashion, i.e., ATP release increased with each decrement in average filter pore size (Fig. 4). In contrast, RBCs from patients with cystic fibrosis (n = 5) did not release ATP in response to mechanical deformation (Fig. 4B). Moreover, ATP values after passage through the filters did not differ from values for ATP determined for cells not subjected to deformation, i.e., the values did not differ from baseline. The RCTT for RBCs from healthy humans and patients with cystic fibrosis was not different for any pore size studied (Fig. 4A). Concentrations of ATP in the RBCs of healthy humans and patients with cystic fibrosis did not differ (Table 2).

Effect of mechanical deformation on ATP release from RBCs of humans with chronic obstructive lung disease. The RCTTs for RBCs of patients with chronic obstructive lung disease (n = 4) did not differ from those observed for RBCs from normal humans and patients with cystic fibrosis (Fig. 5A). RBCs of chronic lung disease patients released ATP in response to mechanical deformation in a manner not unlike that observed for RBCs from patients with cystic fibrosis.

Table 2. Concentration of ATP in RBCs of control subjects (healthy humans), patients with CF, and patients with COPD

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Total ATP, mM/RBC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy humans</td>
<td>5</td>
<td>2.3 ± 0.6</td>
</tr>
<tr>
<td>CF</td>
<td>5</td>
<td>2.2 ± 0.7</td>
</tr>
<tr>
<td>COPD</td>
<td>4</td>
<td>5.9 ± 1.0*</td>
</tr>
</tbody>
</table>

Values are means ± SE; n, no. of experiments. CF, cystic fibrosis; COPD, chronic obstructive lung disease. *P < 0.05 compared with control and CF groups.
with RBCs of healthy humans (Fig. 5B). Amounts of ATP in the RBCs of patients with chronic lung disease were greater than those in healthy humans and humans with cystic fibrosis (Table 2).

**DISCUSSION**

These studies reaffirm our previous finding that ATP is released from the RBCs of rabbits and healthy humans in response to mechanical deformation (24) and extend that observation to demonstrate that this release of ATP requires the activity of CFTR. The contribution of CFTR to deformation-induced ATP release was investigated in two ways, first, by incubation of rabbit RBCs with agents reported to inhibit the activity of CFTR and, second, by comparing the ability of RBCs from healthy humans and patients with cystic fibrosis to release ATP in response to mechanical deformation.

The sulfonylurea glibenclamide, in addition to effects on ATP-sensitive potassium channels (12, 23), has been reported to be a potent inhibitor of the activity of CFTR (22, 23). Incubation of rabbit RBCs with glibenclamide resulted in inhibition of ATP release in response to mechanical deformation (Fig. 1). Importantly, this agent had no effect on the RCTT, an index of the degree of deformation applied to the RBC. Thus the ability of glibenclamide to block ATP release cannot be explained by an effect on RBC deformability. In addition, glibenclamide was without effect on total amounts of ATP present in the RBCs; thus, the lack of ATP release in response to deformation could not be attributed to a failure of ATP synthesis or to depletion of total ATP (Table 1). As stated above, in addition to effects on CFTR, glibenclamide has been reported to inhibit the activity of ATP-sensitive potassium channels in some cells (12, 23). In separate studies in our laboratory, rabbit RBCs were incubated with cromakalim (10 µM, n = 5) and exposed to mechanical deformation. Incubation with cromakalim was without effect on either RCTT or deformation-induced ATP release (data not shown). These experiments provide additional support for the hypothesis that the observed inhibition of deformation-induced ATP release from rabbit RBCs in the presence of glibenclamide was not related to an effect of the latter compound on ATP-sensitive potassium channels.

It was reported that the ability of glibenclamide to inhibit the activity of CFTR is irreversible, i.e., the blockade remains in spite of removal of the inhibitor (23). In the present work, removal of glibenclamide from RBCs after a 30-min incubation did not restore the ability of the RBCs to release ATP in response to mechanical deformation (Fig. 2). The completeness of glibenclamide removal from the suspending medium is demonstrated by the finding that the supernatant of the final RBC wash, when added to RBCs that had not been exposed to glibenclamide, had no effect on ATP release from the latter cells (Fig. 2). Thus the effect of glibenclamide on deformation-induced ATP release from rabbit RBCs was not reversible over the time course of these experiments and is consistent with reports of the effect of this inhibitor on the activity of CFTR.

Finally, to establish that the ability of glibenclamide to inhibit deformation-induced ATP release was related to its effects on CFTR and was not a nonspecific effect of the drug, in separate experiments, rabbit RBCs were incubated with a second purported inhibitor of CFTR activity, namely, niflumic acid (7). The release of ATP in response to deformation was inhibited by incubation with niflumic acid in a manner identical to that seen after incubation with glibenclamide (Figs. 1 and 3). The finding that, in rabbit RBCs, deformation-dependent ATP release was significantly decreased by two chemically dissimilar inhibitors of CFTR activity provides strong pharmacological evidence in support of the hypothesis that the deformation-induced release of ATP from these cells requires CFTR activity.

The finding that human RBCs, like those of rabbits, release ATP in response to mechanical deformation presents a unique opportunity for the study of the contribution of CFTR to ATP release from RBCs. Cystic fibrosis is a genetic disorder characterized clinically by increased concentrations of chloride in sweat and a constellation of symptoms related to chronic pulmonary disease or pancreatic insufficiency or both (8). Despite the fact that patients may have different
Importantly, only those RBCs that possessed the capacity to release ATP in response to mechanical deformation, namely, RBCs of rabbits and healthy humans, but not those of dogs, stimulated endogenous NO synthesis (24). The finding that ATP stimulates endothelial cells to synthesize and release NO (3, 5, 9) coupled with the observations that ATP is released from RBCs of humans and rabbits in response to mechanical deformation (24) and that these RBCs stimulate NO synthesis in the intact pulmonary circulation (24, 25) suggests that the RBC itself may participate in local circulatory control. In this construct, as the RBC is deformed by increments in blood flow through a vessel and/or by reductions in the vessel’s caliber, ATP is released. This ATP, in turn, stimulates local synthesis and release of NO by endothelial cells, leading, ultimately, to an increase in vascular caliber and, thereby, a reduced stimulus for ATP release.

The pulmonary hypertension associated with cystic fibrosis has generally been attributed to extensive alveolar hypoventilation leading to hypoxic pulmonary vasoconstriction (8). The results of the present work suggest that, in addition to hypoxic pulmonary vasoconstriction, the failure of deformation-induced ATP release from RBCs in cystic fibrosis may lead to a decrease in endogenous NO synthesis and thereby contribute to the development of pulmonary hypertension. Identification of the contribution of CFTR to deformation-induced ATP release from RBCs suggests that this channel may play a previously unrecognized role in the regulation of vascular resistance.

We thank Diane Collins, J o Schreiweis, and Kristy Mcgordwell for technical assistance. We also thank Drs. S. Sutera and H. Meiselman for the use of their St. George’s Filtrometers and Dr. T. Forrester for assistance in the measurement of ATP. Finally, we thank J. L. Sprague for inspiration.

This work is supported by National Heart, Lung, and Blood Institute Grants HL-51298, HL-52675, HL-02602, and HL-39226.

Address for reprint requests: R. S. Sprague, Saint Louis Univ., School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104.

Received 23 March 1998; accepted in final form 21 July 1998.

REFERENCES